Locate Bio Ltd

Locate Bio Ltd is a UK-based MedTech and biotech company that specializes in orthobiologics and regenerative medicine. Founded in 2001 and headquartered in Nottingham, the company focuses on developing innovative solutions for musculoskeletal and serious spinal conditions. Their expertise includes drug delivery and tissue scaffold technologies aimed at bone and cartilage regeneration and the treatment of osteomyelitis. One of their key products in development is LDGraft™, a recombinant human bone morphogenetic protein-2 (rhBMP-2) designed for lumbar interbody fusion procedures. LDGraft has received FDA Breakthrough Device designation for anterior lumbar interbody fusion at one level from L3-S1 for patients with degenerative disc disease and is currently in clinical trials. Locate Bio has a strong intellectual property portfolio, having licensed three patented technologies from the Royal College of Surgeons in Ireland, two of which also hold FDA Breakthrough Device designation. The company is committed to advancing high-value orthobiologic assets to market and has recently completed a £10 million Series A funding round to support its growth and product development. Locate Bio collaborates with academic institutions and aims to improve treatment options for spinal and musculoskeletal diseases.

• Employees 24
• Founded 2001
• Total Funding $33355997